EIK1005 / Eikon Therap - LARVOL DELTA

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (clinicaltrials.gov) - P1/2 | N=160 | Not yet recruiting | Sponsor: Eikon Therapeutics

Checkpoint inhibition • dMMR • Mismatch repair • Monotherapy • MSI-H • New P1/2 trial • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Microsatellite Instability • Oncology • Solid Tumor

A novel, internally derived program targeting Werner (WRN) helicase for microsatellite unstable cancers and sensitive cancers that have other defects in DNA repair. EIK1005 is expected to begin Phase 1 clinical testing in Q4, 2025. (Businesswire)

New P1 trial • Microsatellite Instability • Solid Tumor

A Randomized, Double Blind, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of EIK1005 in Healthy Participants. (ANZCTR) - P1 | N=48 | Active, not recruiting | Sponsor: EIKON Therapeutics, Inc. | Not yet recruiting ➔ Active, not recruiting | Initiation date: Aug 2025

Enrollment closed • Trial initiation date • Microsatellite Instability • Solid Tumor

A Randomized, Double Blind, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of EIK1005 in Healthy Participants. (ANZCTR) - P1 | N=48 | Not yet recruiting | Sponsor: EIKON Therapeutics, Inc.

New P1 trial • Microsatellite Instability • Solid Tumor

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline (Businesswire) - "Eikon Therapeutics, Inc...announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses....Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma.... In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers. Eikon’s early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005)..."

Financing • Brain Cancer • Breast Cancer • Melanoma • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer